Arbutus Biopharma

ABUSNASDAQ
$3.12
-0.04-1.27%
At Close: -
$3.13
0.00870.28%
After Hours: 7:28 PM EDT
15 minutes delayed
Arbutus Biopharma (ABUS) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$9.00
Lowest Price Target1
$4.00
Consensus Price Target1
$5.40

want to know what
the Bulls & Bears Say?

Arbutus Biopharma (NASDAQ:ABUS) Stock, Analyst Ratings, Price Targets, Forecasts

Arbutus Biopharma Corp has a consensus price target of $5.4 based on the ratings of 27 analysis. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Chardan Capital on June 7, 2024, June 6, 2024, and June 5, 2024, respectively. With an average price target of $4.67 between HC Wainwright & Co., HC Wainwright & Co., and Chardan Capital, there's an implied 49.16% upside for Arbutus Biopharma Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Mar
0
0
0
0
Apr
0
0
0
0
May
0
0
0
0
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Chardan Capital
JMP Securities
Jefferies
JMP Securities

1calculated from analyst ratings

Analyst Ratings for Arbutus Biopharma

Buy NowGet Alert
06/07/2024Buy Now59.81%HC Wainwright & Co.
Ed Arce
$5 → $5ReiteratesBuy → BuyGet Alert
06/06/2024Buy Now59.81%HC Wainwright & Co.
Ed Arce
$5 → $5ReiteratesBuy → BuyGet Alert
06/05/2024Buy Now27.85%Chardan Capital
Keay Nakae
$4 → $4MaintainsBuyGet Alert
05/03/2024Buy Now27.85%Chardan Capital
Keay Nakae
$4 → $4ReiteratesBuy → BuyGet Alert
04/04/2024Buy Now27.85%JMP Securities
Roy Buchanan
 → $4ReiteratesMarket Outperform → Market OutperformGet Alert
03/01/2024Buy Now27.85%Chardan Capital
Keay Nakae
 → $4ReiteratesBuy → BuyGet Alert
03/01/2024Buy Now59.81%HC Wainwright & Co.
Ed Arce
$6 → $5MaintainsBuyGet Alert
09/12/2023Buy Now91.77%HC Wainwright & Co.
Ed Arce
 → $6ReiteratesBuy → BuyGet Alert
08/04/2023Buy Now91.77%HC Wainwright & Co.
Ed Arce
 → $6ReiteratesBuy → BuyGet Alert
08/04/2023Buy Now91.77%Chardan Capital
Keay Nakae
 → $6ReiteratesBuy → BuyGet Alert
07/11/2023Buy Now91.77%HC Wainwright & Co.
Ed Arce
 → $6ReiteratesBuy → BuyGet Alert
07/06/2023Buy Now91.77%JMP Securities
Roy Buchanan
 → $6ReiteratesMarket Outperform → Market OutperformGet Alert
06/22/2023Buy Now91.77%HC Wainwright & Co.
Ed Arce
 → $6ReiteratesBuy → BuyGet Alert
06/22/2023Buy Now91.77%Chardan Capital
Keay Nakae
 → $6ReiteratesBuy → BuyGet Alert
05/05/2023Buy Now91.77%HC Wainwright & Co.
Ed Arce
 → $6Reiterates → BuyGet Alert
04/28/2023Buy Now91.77%HC Wainwright & Co.
Ed Arce
 → $6Reiterates → BuyGet Alert
04/05/2023Buy Now91.77%HC Wainwright & Co.
Ed Arce
 → $6Reiterates → BuyGet Alert
03/29/2023Buy Now91.77%JMP Securities
Roy Buchanan
 → $6Reiterates → Market OutperformGet Alert
03/20/2023Buy Now91.77%HC Wainwright & Co.
Ed Arce
 → $6Reiterates → BuyGet Alert
03/03/2023Buy Now91.77%Chardan Capital
Keay Nakae
 → $6Reiterates → BuyGet Alert
03/03/2023Buy Now91.77%HC Wainwright & Co.
Ed Arce
 → $6MaintainsBuyGet Alert
11/10/2022Buy Now91.77%HC Wainwright & Co.
Ed Arce
$7.5 → $6MaintainsBuyGet Alert
06/28/2022Buy Now187.66%JMP Securities
Roy Buchanan
$10 → $9MaintainsMarket OutperformGet Alert
03/14/2022Buy Now171.68%HC Wainwright & Co.
Ed Arce
$8 → $8.5MaintainsBuyGet Alert
03/04/2022Buy Now91.77%Chardan Capital
Keay Nakae
$5.5 → $6MaintainsBuyGet Alert
02/02/2022Buy Now59.81%Jefferies
Dennis Ding
$4 → $5UpgradeHold → BuyGet Alert
11/08/2021Buy Now187.66%JMP Securities
Jason Butler
—MaintainsMarket OutperformGet Alert

FAQ

Q

What is the target price for Arbutus Biopharma (ABUS) stock?

A

The latest price target for Arbutus Biopharma (NASDAQ:ABUS) was reported by HC Wainwright & Co. on June 7, 2024. The analyst firm set a price target for $5.00 expecting ABUS to rise to within 12 months (a possible 59.81% upside). 11 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Arbutus Biopharma (ABUS)?

A

The latest analyst rating for Arbutus Biopharma (NASDAQ:ABUS) was provided by HC Wainwright & Co., and Arbutus Biopharma reiterated their buy rating.

Q

When was the last upgrade for Arbutus Biopharma (ABUS)?

A

The last upgrade for Arbutus Biopharma Corp happened on February 2, 2022 when Jefferies raised their price target to $5. Jefferies previously had a hold for Arbutus Biopharma Corp.

Q

When was the last downgrade for Arbutus Biopharma (ABUS)?

A

There is no last downgrade for Arbutus Biopharma.

Q

When is the next analyst rating going to be posted or updated for Arbutus Biopharma (ABUS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arbutus Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arbutus Biopharma was filed on June 7, 2024 so you should expect the next rating to be made available sometime around June 7, 2025.

Q

Is the Analyst Rating Arbutus Biopharma (ABUS) correct?

A

While ratings are subjective and will change, the latest Arbutus Biopharma (ABUS) rating was a reiterated with a price target of $5.00 to $5.00. The current price Arbutus Biopharma (ABUS) is trading at is $3.13, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.